We searched Medline and PubMed with the search terms “HCV” and “hepatitis C virus”, together with “epidemiology”, “clinical manifestation”, “virology”, “diagnosis”, “biopsy”, “treatment”, “drugs”, “immunology”, or “vaccines”. We selected publications mostly from the past 5 years, but did not exclude commonly referenced and highly regarded older publications.
SeminarHepatitis C
Introduction
First discovered in 1989, hepatitis C virus (HCV) is a major health problem affecting more than 170 million people worldwide.1 The percentage of people who are seropositive for anti-HCV antibodies worldwide is estimated to have increased from 2·3% to 2·8% between 1990 and 2005.2 Central and east Asia, north Africa, and the Middle East have the highest prevalence (>3·5%), with moderate prevalence in eastern and western Europe (1·5–3·5%).2 Most patients (80–85%) who become acutely infected cannot clear the virus and progress to chronic infection. This percentage is higher for patients who are co-infected with HIV, and is lower for women and children.3, 4 The severe results of chronic infection are cirrhosis, portal hypertension, hepatic decompensation, and the development of hepatocellular carcinoma, with HCV infection ultimately causing around 350 000 deaths per year.5 In regions of high endemicity, chronic viral hepatitis usually accounts for more than 50% of hepatocellular carcinoma and cirrhosis.6 27% of cases of cirrhosis worldwide can be attributed to HCV, and 25% of hepatocellular carcinoma cases are attributable to HCV infection. Individuals chronically infected with HCV have a decreased quality of life compared with the general population.7
For many years, treatment for chronic HCV has been inadequate (success rates of ∼50%, depending on genotype). The standard of care until 2011 was a combination of subcutaneous pegylated interferon (peginterferon) alfa and oral ribavirin. This combination can lead to a sustained virological response (SVR). Because SVR is regarded as a cure, chronic HCV can be cured by medical treatment, although this does not prevent future reinfection. However, treatment is associated with clinically significant adverse events, and is poorly tolerated and less efficacious in patients with advanced disease.8 The introduction of direct-acting antiviral drugs (DAAs), with two protease inhibitor (PI) drugs licensed in 2011, has increased the number of patients who respond to treatment, and marks a new era of HCV treatment (figure 1).9, 10, 11, 12 New DAAs are in various stages of preclinical and clinical development, leading to optimism about future management of chronic HCV.13
Section snippets
Virology
HCV is a positive-sense, single-stranded 9600 kb RNA virus. A single HCV polyprotein of 3011 aminoacids is translated, and then cleaved by cellular and viral proteases into three structural proteins (core, E1, and E2) and seven non-structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B).14 Related viral sequences have been identified in dogs,15 horses,16 rodents, and bats.17 HCV infections in human populations show extreme genetic diversity, which is partly explained by the long
Immunology
Immune responses to HCV affect the outcome of acute disease and long-term disease progression. Acute responses to HCV include both innate and adaptive branches of the immune system. Polymorphisms in the region of the IFNL3 (also known as IL28B) gene strongly affect spontaneous resolution of infection.29 IFNL3 codes for interferon, lambda 3, which has sustained antiviral activity similar to that of interferon, but with a more restricted receptor distribution. Whether the identified polymorphisms
Epidemiology
HCV is an established parenteral cause of viral hepatitis.38 Transmission via blood transfusion was a major route before universal screening of blood in the developed world, but this transmission route is a problem elsewhere.39 Intravenous drug use, sharing of drug paraphernalia, and reuse of injection needles have become the major routes of HCV transmission.40, 41
The natural history of HCV in pregnancy and in infants born to mothers with HCV is poorly understood, and thus effective methods for
Diagnosis
Diagnosis of HCV relies on detection of antibody to the virus and nucleic acid amplification tests to detect HCV RNA. Antibody tests have improved substantially since their approval by the US Food and Drug Administration in 1990.63 HCV RNA is detected early in infection (∼2 weeks), and will be followed by antibody seroconversion days to weeks later (∼6 weeks), although development of detectable antibody can be delayed, or might not occur at all in immunocompromised patients.64 HCV-specific
Acute HCV
Most acute infections are asymptomatic and anicteric.69 Typically, 10–14 weeks after infection, an increase in serum aminotransaminases occurs.70 The early peak in HCV viral RNA load is sometimes followed by a transient decline,69 and approximately 15–20% of patients will clear acute infection.3, 69, 71 Factors that have been shown to be associated with spontaneous clearance of HCV infection include being female, IFNL3 polymorphisms, high alanine aminotransferase concentrations, presence of
Natural history
HCV infection causes chronic hepatitis, potentially leading to cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma. The onset and accumulation of hepatic fibrosis is clinically silent in the early stages of disease, and identification of disease progression is therefore difficult.79, 80 The yearly incidence of progression of hepatic fibrosis from minimal disease to cirrhosis has been modelled and estimated. The prevalence of biopsy-proven cirrhosis after 20 years of infection has
Treatment
The main goal of treatment for chronic HCV is cure, and thus prevention of disease progression. SVR (defined as HCV RNA <15 IU/mL 12–24 weeks after completion of antiviral therapy) is associated with reduction of both all-cause and liver-related mortality from HCV.84, 85 A combination of peginterferon and ribavirin, given for up to 48 weeks, was previously the mainstay of treatment for all genotypes of HCV, but is being superseded by DAAs (figure 2). No prophylactic vaccine exists, but several
Conclusions
Improved, efficacious and simplified interferon-free and, for most patients, ribavirin-free treatments for HCV infection are now available. Detailed guidelines, treatment algorithms, and licensing information, which will be updated at frequent intervals, are being published to guide clinicians. Simple all-oral regimens of short duration have become a reality. Treatment can now be given to groups of patients for whom interferon was contraindicated. Evidence is emerging that patients on stable
Search strategy and selection criteria
Contributors
All authors contributed equally in writing sections of the manuscript that suited their expertise. All authors reviewed the
References (156)
- et al.
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
J Hepatol
(2006) - et al.
Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
Lancet
(1998) - et al.
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
Lancet
(2001) - et al.
Hepatitis C virus–host interactions, replication, and viral assembly
Curr OpinVirol
(2012) - et al.
Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide
Cell
(1996) - et al.
The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site
Cell
(1996) - et al.
Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men
Gastroenterology
(2009) - et al.
Accuracy of a commercially available assay for HCV genotyping and subtyping in the clinical practice
J Clin Virol
(2013) - et al.
Hepatitis C virus infection: when silence is deception
Trends Immunol
(2003) - et al.
A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection
J Hepatol
(2013)
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial
Lancet Infect Dis
Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance
Gastroenterology
An algorithm for the grading of activity in chronic hepatitis C
Hepatology
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Lancet
Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores
J Hepatol
Antiviral activity of the new DAAs for the treatment of hepatitis C virus infection: virology and resistance
Clin Res Hepatol Gastroenterol
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
Lancet Infect Dis
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
Lancet
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
Lancet
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
Lancet
Viral hepatitis: new data on hepatitis C infection
Pathol Oncol Res
Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence
Hepatology
Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men
Gut
Epidemiology and natural history of HCV infection
Nat Rev Gastroenterol Hepatol
Chronic HCV infection: epidemiological and clinical relevance
BMC Infect Dis
Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study
BMC Gastroenterol
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
N Engl J Med
Boceprevir for untreated chronic HCV genotype 1 infection
N Engl J Med
Telaprevir for previously untreated chronic hepatitis C virus infection
N Engl J Med
Interferon free therapy with direct acting antivirals for HCV
Liver Int
Vaccination for hepatitis C virus: closing in on an evasive target
Expert Rev Vaccines
Characterization of a canine homolog of hepatitis C virus
Proc Natl Acad Sci USA
Nonprimate hepaciviruses in domestic horses, United kingdom
Emerg Infect Dis
Identification of rodent homologs of hepatitis C virus and pegiviruses
MBio
Genetic history of hepatitis C virus in East Asia
J Virol
Genetic diversity and evolution of hepatitis C virus—15 years on
J Gen Virol
The epidemic behavior of the hepatitis C virus
Science
A new evolutionary model for hepatitis C virus chronic infection
PLoS Pathog
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome
Nat Med
Hepatitis C virus entry: beyond receptors
Rev Med Virol
Ultrastructural analysis of hepatitis C virus particles
Proc Natl Acad Sci USA
Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site
Nat Struct Biol
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts
Ann Intern Med
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus
Nat Genet
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection
Science
Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection
Gut
Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection
J Exp Med
Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man
Sci Transl Med
Virus-neutralizing antibodies to hepatitis C virus
J Viral Hepat
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
Proc Natl Acad Sci USA
Cited by (408)
Diabetic patients with chronic hepatitis C virus response compared to non diabetics when treated with directly acting antiviral therapy
2024, Arab Journal of GastroenterologyAcquired knowledge and identified gaps in resistance and human health risk
2023, Antimicrobial Resistance in Wastewater and Human HealthAssessing the proportion of patients with hepatitis C treated before and after initiation of an ambulatory pharmacist-led hepatitis C program: A retrospective analysis
2023, Journal of the American Pharmacists Association